Objective To explore the efficacy and safety of albumin-bound paclitaxel combined with platinum-based agents as first-line adjuvant chemotherapy for epithelial ovarian cancer. Methods A total of 330 eligible patients with epithelial ovarian cancer who received initial treatment at the Gynecologic Oncology Department of Sun Yat-sen Memorial Hospital， Sun Yat-sen University between January 25， 2018 and September 28， 2021 were enrolled in this study. These patients were retrospectively divided into two cohorts： Cohort 1 （n=142）， designated as the nab-paclitaxel group， and Cohort 2 （n=188）， designated as the paclitaxel group. The feasibility of nab-paclitaxel as a first-line treatment was compared and evaluated. Results No statistically significant difference was observed in median follow-up duration between the nab-paclitaxel and paclitaxel groups （21.70 months vs. 24.62 months， P=0.109）. The median progression-free survival （PFS） did not differ significantly between the two groups （17.00 months vs. 20.00 months， P=0.488）. However， the nab-paclitaxel group demonstrated higher treatment feasibility （83.8% vs.69.1%， P=0.002） and a lower incidence of myelosuppression of varying degrees （73.2% vs. 86.2%， P=0.003）. Quality-of-life assessments revealed that the nab-paclitaxel group experienced milder gastrointestinal reaction， with statistical significance. Conclusion In the first-line adjuvant chemotherapy for epithelial ovarian cancer， albumin-bound paclitaxel+platinum may be used as an alternative regimen， especially for patients who are allergic to paclitaxel or have severe gastrointestinal reactions.

HELLP syndrome（hemolysis，elevated liver enzymes，and thrombocytopenia syndrome）is a severe pregnancy-related complication characterized by high maternal and fetal mortality rates.Fulminant HELLP syndrome，a critical subtype of HELLP syndrome，is marked by rapid disease progression，significantly abnormal laboratory indices（e.g.，AST>2000 U/L or LDH>3000 U/L），and multi-organ dysfunction.This article reviews the pathophysiological mechanisms，clinical manifestations，diagnostic criteria，and therapeutic principles of fulminant HELLP syndrome.

Anemia during pregnancy and the postpartum period is a global public health issue，significantly associated with adverse obstetric outcomes，and iron deficiency （ID） is its primary cause. Currently，novel high-dose intravenous iron formulations，which allow single-dose infusion of ≥1000 mg within 15-30 minutes，have been approved for clinical use in China. However，obstetricians and gynecologists lack sufficient understanding of their efficacy and safety in pregnant and postpartum women. This article discusses the application of high-dose intravenous iron in pregnant and postpartum women.

Objective To investigate the current state of clinical diagnosis and treatment for cervical cancer in China，focusing on systemic therapeutic practices. By surveying clinicians on biomarker testing applications，treatment regimen considerations and preferences，this study is aimed to identify unmet clinical needs and provide a reference for standardization of diagnosis and treatment. Methods A nationwide sampling survey combining online questionnaires and in-depth interviews was conducted from August to September 2025，involving 300 clinicians （30 experts participated in interviews，270 completed questionnaires）. The survey primarily covered the admission of cervical cancer patients，patient stage and pathology types，biomarker testing，treatment strategies for locally advanced，recurrent，or metastatic cervical cancer （including first-，second- or later-line settings）. It also covered clinicians’ insights regarding immune checkpoint inhibitors （ICI） and antibody-drug conjugates （ADC）. Results A total of 270 valid questionnaires and 30 valid expert interviews were obtained. At diagnosis，early-stage （ⅠA1-ⅠB2，ⅡA1），locally advanced （ⅠB3，ⅡA2-ⅣA），and recurrent/metastatic （ⅣB） cervical cancer （r/m CC） accounted for 32.2%，35.8%，and 31.9%，respectively. Squamous cell carcinoma was predominant （74.9%）. Among the patients，75.0% were recommended for programmed death-ligand 1 （PD-L1） and other biomarker testing，with an actual testing rate of 53.7%. For locally advanced cervical cancer，concurrent chemoradiotherapy （CCRT） with or without ICIs was the first choice. For r/m CC，first-line treatment was mainly ICI combined with chemotherapy±anti-angiogenic agents （71%）. For second- or later-line treatment，combination regimens predominated （approximately 75%）. Among patients not previously treated with ICIs，chemotherapy combined with ICIs was the first choice，with chemotherapy combined with ICIs and chemotherapy combined with anti-angiogenic agents accounting for 37% and 34% of cases，respectively. For patients with prior ICI exposure，chemotherapy combined with ICIs and chemotherapy combined with anti-angiogenic agents were the first choices at 30% and 23%，respectively；regimens containing ADCs accounted for approximately 30%. Conclusions This study reveals the current status of cervical cancer diagnosis and treatment in China，highlighting gaps in biomarker testing recommendations and clinical application. It identifies core considerations and treatment options for locally advanced and r/m CC in first-line，providing data support for advancing standardized clinical practice.

Evans Syndrome（ES）is a rare autoimmune disease characterized by the presence of at least two types of autoimmune cytopenia（AIC）.The etiology of ES is complex and diverse and secondary ES is relatively common.Its occurrence and development are related to primary diseases such as lymphoproliferative disorders，infections，and autoimmune diseases，and the fatality rate is relatively high.When ES is combined with pregnancy，the incidence of perinatal complications is high，which may lead to serious maternal-fetal complications.This article elaborates and summarizes the relevant researches on Evans syndrome at home and abroad，aiming to explore the etiology of Evans syndrome and its impact on pregnancy，provide certain theoretical support for the clinical diagnosis and treatment of ES combined with pregnancy，and improve the maternal and infant outcomes.

The rapid and successive formation of arterial and venous thromboses across multiple organ systems within a short period is commonly referred to as a“thrombotic storm”，and catastrophic antiphospholipid syndrome（CAPS）is a rare but highly lethal subtype of this thromboinflammatory disease.Despite its low incidence，CAPS progresses rapidly，has a high mortality rate，and is often misdiagnosed or diagnosed too late.In pregnant patients， especially，it poses a severe threat to both maternal and fetal health.Timely identification and prompt and active treatment have become important clinical issues in improving outcomes.This article focuses on the early recognition and therapeutic strategies for CAPS.

Acute fatty liver of pregnancy（AFLP）is a kind of extremely dangerous pregnancy-specific disease with a low incidence rate，about which most doctors are in lack of understanding.AFLP often occurs in late pregnancy，characterized by liver failure，coagulation dysfunction，and multiple organ dysfunction.Its onset is sudden and progression is rapid.If it is not intervened in a timely manner，the maternal and infant mortality rates are extremely high.In recent years，with the release of domestic clinical management guidelines for AFLP，the understanding of this disease in clinical work has been gradually improved.The development of multidisciplinary diagnosis and treatment models for critically ill patients has significantly increased the success rate of AFLP treatment.This article elaborates on the key indicators of management of severe AFLP and the multidisciplinary collaborative diagnosis and treatment model，in order to provide reference for the management of severe AFLP.

Thrombocytopenia is a common hematologic complication during pregnancy，and immune thrombocytopenia and thrombotic microangiopathy（TMA）are rare but important etiologies， requiring precise differentiation due to their distinct pathological mechanisms，treatment strategies，and maternal-fetal risks. Immune thrombocytopenia refers to thrombocytopenia mediated by abnormal immune activation. The diagnosis of primary immune thrombocytopenia（ITP） should exclude secondary ITP due to other causes （such as autoimmune diseases， infections， drugs， tumors， etc.），and the treatment for ITP primarily involves glucocorticoids and intravenous immunoglobulin.TMA is a group of heterogeneous diseases with the core pathological features of microvascular thrombosis， presenting with microangiopathic hemolysis，thrombocytopenia，and multi-organ dysfunction，which requires specific interventions based on different disease types，such as pregnancy termination，plasma exchange，or complement inhibitors.This article systematically outlines the key points for differential diagnosis of ITP and TMA based on clinical features， laboratory tests and molecular markers，emphasizing the critical importance of initiating targeted therapy promptly in improving maternal-fetal prognosis.

Pregnancy-associated thrombotic thrombocytopenic purpura（TTP）is a rare obstetric complication characterized by thrombocytopenia，microangiopathic hemolytic anemia，and multi-organ dysfunction.The hypercoagulable state of pregnancy，combined with deficient or inhibited ADAMTS13 enzyme activity，significantly exacerbates disease risk，resulting in high mortality if untreated.This article systematically reviews the pathological mechanisms，early diagnostic biomarkers，and intervention strategies for gestational TTP.A multidisciplinary clinical management pathway is proposed and the future research directions based on the latest scientific advances are discussed.

Objective To investigate the application value of single nucleotide polymorphism （SNP）linkage analysis based on next-generation sequencing （NGS） technology in preimplantation genetic testing （PGT）of families with autosomal dominant polycystic kidney disease （ADPKD）induced by novel mutations. Methods A family with ADPKD induced by novel mutations was selected，and whole exome sequencing and karyotyping were used to determine the pathogenic mutations of the family. To block the inheritance of the disease，blastocyst culture was performed after in vitro fertilization，blastocyst trophoblast cell samples were biopsied，and multiple annealing and looping-based amplification cycles were used for whole genome amplification of the biopsied cells. Sanger sequencing and next-generation sequencing（NGS）-based single nucleotide polymorphism （SNP） haplotyping were used to detect the state of the gene mutations. Copy number variation （CNV） analysis was used for chromosomal aneuploidy screening of the embryos. Prenatal diagnosis in the second trimester of pregnancy was preformed to verify the PGT outcomes. Results A novel c.2098-2A>G mutation in PKD1 gene was found in the proband. A total of 3 blastocysts formed after intracytoplasmic sperm injection were biopsied. One blastocyst was mutation-free and euploid，and the euploid embryo underwent frozen embryo transplantation (FET) to achieve clinical pregnancy. Prenatal diagnosis in the second trimester confirmed that the fetus did not carry heterozygous PKD1 gene c.2098-2A>G mutation. Conclusions Our study is the first PGT report targeting the PKD1 gene c.2098-2A>G mutation，which extends the mutation spectrum of PKD1 gene and provides a new line of thinking about the molecular diagnosis and genetic counseling for ADPKD. Combining NGS-based SNP haplotyping for PGT-M with invasive prenatal diagnosis is an effective approach to block the vertical transmission of ADPKD and can be applied to prevent other monogenic genetic diseases.

The accurate diagnosis and prompt management of pregnancy-associated complications are crucial for safeguarding the well-being of both mothers and infants.This is particularly true for diseases presenting with similar clinical manifestations yet having markedly distinct treatment strategies.The HELLP syndrome（characterized by hemolysis，elevated liver enzymes，and thrombocytopenia）and postpartum hemolytic uremic syndrome（PHUS），as typical examples of pregnancy-related thrombotic microangiopathy（TMA），share comparable clinical features but possess fundamental pathological disparities.Both diseases have an insidious onset and progress rapidly， and misdiagnosis or delayed diagnosis is not uncommon，which significantly compromises patient prognosis.Thus，the accurate discrimination between the HELLP syndrome and PHUS is pivotal for enhancing diagnostic and therapeutic efficacy and reducing maternal mortality.This article comprehensively analyzes the similarities and differences in the pathogenesis， clinical characteristics， and laboratory findings of the two conditions. It proposes a differential diagnosis approach based on multidisciplinary cooperation and underlines the significance of early recognition in improving prognosis. By reviewing the latest domestic and international guidelines and clinical practices， key differential diagnostic points are summarized， aiming to offer a reference for clinical decision-making.

Postpartum hemolytic uremic syndrome refers to a serious life-threatening syndrome characterized by acute microvascular hemolytic anemia，thrombocytopenia，and acute renal failure that occurs after childbirth.If not treated，it will lead to a mortalityrate of up to 90%.The etiology is still unknown.Current research suggests that endothelial dysfunction，coagulation fibrinolysis imbalance，and abnormal activation of the complement system are the main pathogenesis of this syndrome.Although the incidence is extremely low，the mortality rate is high and the treatment options are limited.In recent years，with the deepening of research on the complement system，new treatment methods such as complement inhibitors have brought new hope to PHUS patients.This article elaborates and discusses its pathogenesis，diagnosis and treatment.

The article systematically reviews the safety evidence and clinical application standards of antiplatelet and anticoagulant drugs during pregnancy by retrieving and analyzing domestic and international guidelines，consensus，and clinical studies from the past decade. It focuses on maternal and fetal safety，differences in guideline recommendations，medication strategies for special cases，and management pathways. Key findings include：（1）Aspirin is the recommended antiplatelet drug for preeclampsia prevention，with no significant maternal or fetal risks. Low-molecular-weight heparin （LMWH） has become the first choice for anticoagulation during pregnancy due to its inability to cross the placenta and high safety. Unfractionated heparin （UFH） is mostly used for transition before delivery，while warfarin and direct oral anticoagulants （DOACs） are restricted due to fetal risks. （2）There are detailed differences among different guidelines regarding the initiation time of aspirin and the dosage of LMWH.（3） Special cases such as mechanical heart valves and hereditary thrombophilia，a multidisciplinary collaboration is required to develop individualized plans； additionally，a management pathway of "individualized risk assessment-drug monitoring-multidisciplinary collaboration" is proposed. The selection of antithrombotic drugs during pregnancy should take "maternal and fetal safety" as the core，and prioritize the use of aspirin and LMWH. In the future，more high-quality studies are needed to clarify the safety of DOACs and the individualized medication strategies for such drugs.